An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...

Efficacy and safety of oxybutinin chloride topical gel for overactive bladder: a randomised, double blind, placebo controlled multicenter study. J. Urol. 181 , 1764–1772 (2009).

Michael Franks, MD, Emmanuel Chartier-Kastler, MD, Michael B. Chancellor, MD ...

For the first time in over 25 years (since the approval of oxybutynin in 1972), better medications are available for the overactive bladder. With the recent approval of tolterodine and oxybutynin ...

THURSDAY, Jan. 2, 2025 (HealthDay News) -- Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy ...

Medical experts share their answers to all your questions on bladder problems, from urinary tract infections to odd urine ...

(HealthDay News) — Gemtesa (vibegron) has been approved by the US Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy for benign prostatic ...

THURSDAY, Jan. 2, 2025 (HealthDay News) — Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy ...

As a result, the bladder muscles are relaxed when filling up with urine, which allows the bladder to contain its urine instead of sending the brain signals of urinary urgency. When this happens, ...